Pancreatic Neuroendocrine Tumor

• CLINICAL_TRIALS trial_result · 2023-03-30
  Clinical Trial Update: Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors [Phase 3]

  Phase III study results for surufatinib in advanced pancreatic neuroendocrine tumors completed.

• FDA approval · 2023-02-21
  FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)

  FDA approved a supplemental application to Heritage Pharmaceuticals (Avet) for octreotide acetate, a generic product, under an ANDA.

• CLINICAL_TRIALS trial_result · 2022-10-19
  Clinical Trial Update: Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors [Phase 2]

  Phase 2 trial evaluating temozolomide with or without capecitabine in advanced pancreatic neuroendocrine tumors, including subtypes such as …

• CLINICAL_TRIALS trial_result · 2022-07-05
  Clinical Trial Update: Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study [Phase 2]

  Phase 2 clinical trial investigating capecitabine with temozolomide and radiolabeled peptide therapy (Lutetium-177) for midgut and pancreati…

• FDA approval · 2022-04-11
  FDA Approved: SUNITINIB MALATE — Original Application (Dr.Reddys Laboratories Inc)

  FDA approved a generic version of sunitinib malate (SUNITINIB MALATE) from Dr. Reddy's Laboratories Inc under Original Application.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2022-04-05
  Clinical Trial Update: Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery [Phase 2]

  Phase 2 clinical trial update for sapanisertib in metastatic or unresectable pancreatic neuroendocrine tumors (PENET G1/G2; refractory), wit…

• FDA approval · 2021-12-06
  FDA Approved: SUNITINIB MALATE — Original Application (Mylan Pharmaceuticals Inc.)

  FDA approved a generic version of sunitinib malate submitted by Mylan Pharmaceuticals Inc., for use in cancer indications shared with the re…

• FDA approval · 2021-10-18
  FDA Approved: EVEROLIMUS — Original Application (Par Health USA, LLC)

  FDA approved Par Health USA, LLC's Original Application for EVEROLIMUS (a generic version of everolimus). The approval enables the generic p…

• FDA approval · 2021-08-30
  FDA Approved: SUTENT — Supplemental Application (U.S. Pharmaceuticals)

  The FDA approved a supplemental application for Sutent (sunitinib malate) submitted by U.S. Pharmaceuticals, enabling an updated indication …

• FDA approval · 2021-08-16
  FDA Approved: SUNITINIB MALATE — Original Application (NorthStar RxLLC)

  FDA approved the original application for sunitinib malate, authorizing a generic version of the cancer drug from NorthStar RxLLC.

• CLINICAL_TRIALS trial_result · 2021-06-10
  Clinical Trial Update: VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors [Phase 1, Phase 2]

  A phase 1/2 clinical trial evaluating VEGFR/PDGFR dual kinase inhibitor X-82 in combination with Everolimus for pancreatic neuroendocrine tu…

• FDA approval · 2021-02-11
  FDA Approved: EVEROLIMUS — Original Application (NorthStar RxLLC)

  FDA approved NorthStar RxLLC's original application (ANDA) for Everolimus, a generic version of the mTOR inhibitor. The approval enables a g…

• CLINICAL_TRIALS trial_result · 2020-12-30
  Clinical Trial Update: Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors [Phase 2]

  Phase 2 trial evaluating capecitabine, temozolomide, and bevacizumab for metastatic or unresectable pancreatic neuroendocrine tumors has com…

• CLINICAL_TRIALS trial_result · 2020-12-30
  Clinical Trial Update: Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg [Phase 2]

  Phase 2 trial updating the efficacy and safety of lanreotide Autogel in pancreatic and midgut neuroendocrine tumors after progression on pri…

• CLINICAL_TRIALS trial_result · 2020-12-02
  Clinical Trial Update: Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery [Phase 2]

  Phase 2 clinical trial of everolimus in patients with pancreatic neuroendocrine tumors with liver metastases, previously treated with surger…

• CLINICAL_TRIALS trial_result · 2020-07-09
  Clinical Trial Update: RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors [Phase 1, Phase 2]

  Phase 1/2 clinical trial evaluating RAD001 (everolimus) combined with temozolomide in advanced pancreatic neuroendocrine tumors; study statu…

• CLINICAL_TRIALS trial_result · 2020-06-17
  Clinical Trial Update: Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery [Phase 1, Phase 2]

  Phase 1/2 trial evaluating temozolomide with pazopanib in advanced, unresectable pancreatic neuroendocrine tumors; study completed with resu…

• FDA approval · 2020-06-08
  FDA Approved: EVEROLIMUS — Original Application (Hikma Pharmaceuticals USA Inc.)

  FDA approved Hikma Pharmaceuticals USA Inc.'s generic Everolimus under an Original Application, enabling the sale of a generic version of th…

• CLINICAL_TRIALS trial_result · 2020-03-23
  Clinical Trial Update: Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery [Phase 2]

  Phase 2 trial evaluating Ziv-Aflibercept for pancreatic neuroendocrine tumors; study completed with results posted in 2020.

• CLINICAL_TRIALS trial_result · 2020-03-04
  Clinical Trial Update: Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib [Phase 2]

  A Phase 2 trial evaluating the efficacy of rechallenge with sunitinib in metastatic pancreatic neuroendocrine tumor that previously failed s…

• FDA approval · 2020-02-13
  FDA Approved: AFINITOR — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for Afinitor (everolimus) from Novartis Pharmaceuticals Corporation.

• FDA approval · 2020-02-03
  FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)

  FDA approved a supplemental application for octreotide acetate from Heritage Pharmaceuticals Inc. (Avet Pharmaceuticals Inc.).

• FDA approval · 2020-02-03
  FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)

  The FDA approved a supplemental application for octreotide acetate from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. under …

• CLINICAL_TRIALS trial_result · 2019-10-02
  Clinical Trial Update: Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors [Phase 2]

  Phase II study of ibrutinib in advanced carcinoid and pancreatic neuroendocrine tumors has completed with posted results.

• FDA approval · 2019-04-11
  FDA Approved: SANDOSTATIN — Supplemental Application (Novartis Pharmaceuticals Corporation)

  The FDA approved a supplemental application for Sandostatin (octreotide acetate) from Novartis Pharmaceuticals Corporation under NDA 019667.